Summary of Results
| FAB Subtype . | Patient No. . | EpoR Analysis . | 3H-Thymidine Incorporation on Epo . | STAT5 Activation on Epo . | GATA-1 Activation on Epo . |
|---|---|---|---|---|---|
| RA | 1 | — | Low | Low pos/no | No |
| 2 | — | No | No | No | |
| 3 | Normal | — | — | — | |
| RARS | 4 | Normal | — | — | — |
| RAEB | 5 | Normal | — | — | — |
| 6 | — | No | No | No | |
| 7 | — | No | No | No | |
| 8 | Normal | No | No | No | |
| 9 | Normal | — | — | — | |
| RAEB-t | 10 | — | No | No | No |
| 11 | — | No | Low pos | No | |
| 12 | Normal | — | — | — | |
| 13 | Normal | No | No | Low | |
| 14 | Normal | No | No | Low | |
| 15 | — | No | No | Low | |
| CMML | 16 | Normal | No | Low pos/no | Low |
| 17 | — | No | No | No | |
| 18 | Normal | — | — | — | |
| 19 | — | Low | Low pos/no | Low | |
| 20 | — | No | No | No | |
| 21 | — | Low | No | Low |
| FAB Subtype . | Patient No. . | EpoR Analysis . | 3H-Thymidine Incorporation on Epo . | STAT5 Activation on Epo . | GATA-1 Activation on Epo . |
|---|---|---|---|---|---|
| RA | 1 | — | Low | Low pos/no | No |
| 2 | — | No | No | No | |
| 3 | Normal | — | — | — | |
| RARS | 4 | Normal | — | — | — |
| RAEB | 5 | Normal | — | — | — |
| 6 | — | No | No | No | |
| 7 | — | No | No | No | |
| 8 | Normal | No | No | No | |
| 9 | Normal | — | — | — | |
| RAEB-t | 10 | — | No | No | No |
| 11 | — | No | Low pos | No | |
| 12 | Normal | — | — | — | |
| 13 | Normal | No | No | Low | |
| 14 | Normal | No | No | Low | |
| 15 | — | No | No | Low | |
| CMML | 16 | Normal | No | Low pos/no | Low |
| 17 | — | No | No | No | |
| 18 | Normal | — | — | — | |
| 19 | — | Low | Low pos/no | Low | |
| 20 | — | No | No | No | |
| 21 | — | Low | No | Low |